MannKind wins Breakthrough T1D grant for INHALE-1ST pediatric Afrezza trial

MannKind Corporation

MannKind Corporation

MNKD

0.00
  • MannKind won a Breakthrough T1D grant to support its INHALE-1ST trial of Afrezza in newly diagnosed pediatric type 1 diabetes patients.
  • The study tests Afrezza with once-daily basal insulin in youth aged 10 to under 18, tracking outcomes over 13 weeks.
  • The award follows FDA clearance in May 2026 for Afrezza use in children aged 6 and older.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230900PRIMZONEFULLFEED9750842) on June 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.